6533b7d3fe1ef96bd1261693

RESEARCH PRODUCT

Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.

Begoña Soler-lópezVicente Balanzá-martínezPilar García-garcíaBenjamín Piñeiro-dieguez

subject

AdultMalePediatricsmedicine.medical_specialtyCross-sectional studySubstance-Related DisordersComorbidity03 medical and health sciencesPsychiatric comorbidity0302 clinical medicinemental disordersOutpatientsDevelopmental and Educational PsychologymedicinePrevalenceHumansSex DistributionPsychiatryMethylphenidatebusiness.industryMood DisordersMental Disordersmedicine.diseaseComorbidityAnxiety Disorders030227 psychiatryClinical PsychologyCross-Sectional StudiesMood disordersAttention Deficit Disorder with HyperactivityMethylphenidateAnxietyObservational studyFemalemedicine.symptomSubstance usebusiness030217 neurology & neurosurgerymedicine.drug

description

Objective: The CAT ( Comorbilidad en Adultos con TDAH) study aimed to quantify and characterize the psychiatric comorbidity at the time of diagnosis of ADHD in adult outpatients. Method: Cross-sectional, multicenter, observational register of adults with ADHD diagnosed for the first time. Results: In this large sample of adult ADHD ( n = 367), psychiatric comorbidities were present in 66.2% of the sample, and were more prevalent in males and in the hyperactive-impulsive and combined subtypes. The most common comorbidities were substance use disorders (39.2%), anxiety disorders (23%), and mood disorders (18.1%). In all, 88.8% patients were prescribed pharmacological treatment for ADHD (in 93.4% of cases, modified release methylphenidate capsules 50:50). Conclusion: A high proportion of psychiatric comorbidity was observed when adult outpatients received a first-time diagnosis of ADHD. The systematic registering of patients and comorbidities in clinical practice may help to better understand and manage the prognostic determinants in adult ADHD.

10.1177/1087054713518240https://pubmed.ncbi.nlm.nih.gov/24464326